



PTO/SB/08a/b (07-05)

Approved for use through 09/30/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/591,608 ~~ Conf. No. 3117
				Filing Date	September 5, 2006
				First Named Inventor	John IENI et al.
				Art Unit	Not Yet Assigned
				Examiner Name	Lin, Bryan
Sheet	1	of	1	Attorney Docket Number	61368-233549

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	A1	Partial European Search Report	07-31-2008	Eisai Co., Ltd.		
	A2	EP 1 116 716	07-18-2001	Eisai Co., Ltd.		
	A3	WO 99/15159	04-01-1999	Nova Molecular, Inc.		
	A4	WO 00/03746	01-27-2000	The Brigham and Women's Hospital, Inc.		
	A5	WO 00/56403	09-28-2000	The Brigham and Women's Hospital, Inc.		
	A6	WO 01/96311	12-20-2001	Bristol-Myers Squibb Company		
	A7	WO 03/068168	08-21-2003	The Brigham and Women's Hospital, Inc.		
	A8	WO 2004/034963	04-29-2004	Eisai Co., Ltd.		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	A9	Black et al., "Efficacy and Tolerability of Donepezil in Vascular Dementia: Positive Results of a 24-Week, Multicenter, International, Randomized, Placebo-Controlled Clinical Trial," Stroke 34:2323-2332, 2003.		
	A10	Erkinjuntti et al., "An Open-Label Extension Trial of Galantamine in Patients with Probable Vascular Dementia and Mixed Dementia," Clinical Therapeutics, 25(6):1765-1782, 2003.		
	A11	Kalimo et al., "CADDASIL: A Common Form of Hereditary Arteriopathy Causing Brain Infarcts and Dementia," Brain Pathology, 12:371-384, 2002.		
	A12	Moretti et al., "Rivastigmine in Subcortical Vascular Dementia: An Open 22-month Study," Journal of the Neurological Sciences, 203-204:141-146, 2002.		
	A13	Roman et al., "Perspectives in the Treatment of Vascular Dementia," Drugs of Today, 36(9):641-653, 2000.		
	A14	Roman G., "Subcortical Ischaemic Vascular Dementia," Lancet Neurology, 1:426-36, 2002.		
	A15	Saif et al., "Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL)", Practical Neurology, 4:50-55, 2004.		
	A16	Wilkinson et al., "Donepezil in Vascular Dementia: A Randomized, Placebo-Controlled Study," Neurology, 61:479-486, 2003.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

#980608